The most common adverse events experienced by patients who received MK-3475 included fatigue, rash, diarrhea, nausea, cough, joint pain, fever and itching. Seven MK-3475 related Grade 3/4 adverse events were reported as potentially “immune related.”
Merck recently initiated a global, randomized, Phase II clinical trial to evaluate MK-3475 versus standard chemotherapy for participants with advanced melanoma whose disease has progressed after prior therapy (reference: NCT01704287). Participants will be randomized to receive one of two doses of MK-3475 or investigator-choice chemotherapy. For further information, please visit http://www.clinicaltrials.gov.
About PD-1 and MK-3475
Research has shown that PD-1, an immune checkpoint receptor, helps to confer immune resistance for some cancers allowing tumor cells to grow and proliferate unchecked. MK-3475 is a monoclonal antibody designed to target PD-1 to disrupt the role PD-1 plays in resisting the immune system.About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube. Merck Forward-Looking Statement This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV